DNDN Related Major News

May 9, 2013 08:31 AM Dendreon Corp (DNDN) Reports In-Line Q1 Loss of 48c/Share

Feb 25, 2013 07:31 AM Dendreon Corp (DNDN) Posts Q4 Loss of 26c/Share

Jan 7, 2013 09:06 AM Dendreon (DNDN) Q4 Revs Top Views

Nov 2, 2012 08:34 AM Dendreon Corp (DNDN) Posts Narrower than Expected Q3 Loss of 33c/Share

Jul 30, 2012 04:11 PM Dendreon (DNDN) Announces Strategic Restructuring, Cutting 600 Jobs

Jul 30, 2012 04:07 PM Dendreon Corp (DNDN) Misses Q2 EPS by 2c

May 7, 2012 04:24 PM Dendreon Corp (DNDN) Posts Better-Than-Expected Q1 Loss of 59c/Share

Feb 27, 2012 08:32 AM Dendreon Corp (DNDN) Reports Very Strong Q4 Results

Feb 1, 2012 06:31 AM Dendreon (DNDN) Elects John Johnson as Next CEO; Mitch Gold to Serve as Chairman

Nov 2, 2011 04:00 PM Dendreon Corp (DNDN) Posts Q3 Loss of $0.56, Sales Top Expectations

Aug 3, 2011 04:03 PM Dendreon (DNDN) Posts Narrower than Expected Q2 Loss; Withdraws PROVENGE Guidance

May 2, 2011 04:02 PM Dendreon Corp. (DNDN) Reports Smaller Than Expected Q1 Loss

Mar 10, 2011 02:37 PM Dendreon (DNDN) Moves Higher After FDA Approves Expanded Manufacturing

Mar 1, 2011 03:01 PM Dendreon Corp. (DNDN) Reports Q4 Loss of 64c

Nov 17, 2010 02:54 PM Dendreon (DNDN) Wins Medicare Panel's Vote for Survival Benefits of Provenge

Nov 3, 2010 04:03 PM Dendreon (DNDN) Reports Winder Q3 Loss, On Lower Sales - Stock Halted

May 10, 2010 05:35 PM Dendreon (DNDN) Reports Q1 Loss of 96c

Apr 29, 2010 04:00 PM Dendreon's (DNDN) Prostate Cancer Drug Provenge Receives FDA Approval

Mar 3, 2010 07:03 PM Updated Data On Dendreon's (DNDN) Prostate Cancer Drug PROVENGE Shows Additional Survival Benefits

Feb 22, 2010 04:01 PM Dendreon Corp. (DNDN) Posts Q4 Loss of $0.28, In-Line With Views; Revs Miss

Nov 11, 2009 04:04 PM Dendreon (DNDN) Reports Q3 Loss of $0.40, Misses by 19c

Nov 2, 2009 08:43 AM Dendreon (DNDN) Completes Submission of Amended Biologics License Application for PROVENGE®

May 6, 2009 07:35 AM Dendreon (DNDN) Reports Q1 Loss of $0.16, Beats by 2c

Apr 28, 2009 02:04 PM Dendreon (DNDN) Said PROVENGE Significantly Prolongs Survival for Men With Prostate Cancer

Apr 14, 2009 08:35 AM Dendreon (DNDN) Reports Phase 3 IMPACT Study of PROVENGE Meets Primary Endpoint

Mar 12, 2009 04:31 PM Dendreon (DNDN) Reports Q4 Loss of $0.09

Aug 12, 2008 07:57 AM Dendreon (DNDN) Reports Mixed Q2 Results

Dec 13, 2007 01:06 PM UPDATE: Dendreon (DNDN) Surges On Request For Congressional Hearing on FDA Provenge Review